<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05796921</url>
  </required_header>
  <id_info>
    <org_study_id>113/2022/PO</org_study_id>
    <nct_id>NCT05796921</nct_id>
  </id_info>
  <brief_title>Lacticaseibacillus Rhamnosus CA15 (DSM 33960) Strain as a New Driver in Restoring the Normal Vaginal Microbiota</brief_title>
  <official_title>Lacticaseibacillus Rhamnosus CA15 (DSM 33960) Strain as a New Driver in Restoring the Normal Vaginal Microbiota: a Randomized, Double-blind, Placebo-controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Agnese Maria Chiara Rapisarda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ProBioEtna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universita degli Studi di Catania</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the present randomized double-blind placebo-controlled trial is to evaluate the&#xD;
      efficacy of a probiotic formulation, containing the probiotic strain Lacticaseibacillus&#xD;
      rhamnosus CA15 (DSM 33960), in the treatment of vaginal dysbiosis in terms of: (i) modulation&#xD;
      of the microbiota (increase of lactobacilli and decrease of pathogens), (ii) reduction of&#xD;
      clinical signs of inflammation, (iii) improvement of quality of life.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the present randomized double-blind placebo-controlled study is to evaluate the&#xD;
      ability of the potential probiotic Lacticaseibacillus rhamnosus CA15 (DSM 33960) strain,&#xD;
      orally administrated, to balance the vaginal microbiota of women with vaginal dysbiosis. Two&#xD;
      hundred women, with signs and symptoms of vaginal dysbiosis, are recruited and randomly&#xD;
      allocated to receive oral capsules containing the L. rhamnosus CA15 (DSM 33960) strain or&#xD;
      placebo once daily for 10 days. Clinical and microbiological parameters are evaluated in&#xD;
      three scheduled appointments: at baseline (T0), 10 days after the start of the treatment&#xD;
      (T1), and 30 days after the end of the treatment (T2). In addition, at baseline (T0) and 30&#xD;
      days after the end of the treatment (T2), the quality of life will be evaluated through a&#xD;
      quality of life assessment questionnaire.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2, 2023</start_date>
  <completion_date type="Anticipated">March 30, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 29, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized double-blind placebo-control</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiota</measure>
    <time_frame>Baseline; end of the treatment (10 days); wash-out (3 months)</time_frame>
    <description>Change in the composition of the vaginal microbiota (significant reduction of pathogens responsible for vaginal dysbiosis and concomitant increase in lactobacilli)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Symptomatology</measure>
    <time_frame>Baseline; end of the treatment (10 days); wash-out (3 months)</time_frame>
    <description>Change of signs (leucorrhoea, vulvovaginal erythema/edema) and symptoms (vulvar discomfort, burning, itching) associated to vaginal dysbiosis. Clinical signs and symptoms will be evaluated through a severity score on a scale of 0 (absent or normal) to 3 (severe).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Sign</measure>
    <time_frame>Baseline; end of the treatment (10 days); wash-out (3 months)</time_frame>
    <description>Absence of inflammation according to Amsel's criteria and Nugent score between 0 and 3</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Well-being</measure>
    <time_frame>Baseline; end of the treatment (10 days); wash-out (3 months)</time_frame>
    <description>Change in the quality of life, based on the Short Form-36 (SF-36) questionnaire. Values ranging from 0 to 100 indicate worst and better outcomes, respectively.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Bacterial Vaginosis</condition>
  <condition>Candidosis Vaginal</condition>
  <condition>Urinary Tract Infections</condition>
  <arm_group>
    <arm_group_label>Active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 daily capsule of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain (15 billion of Colony Forming Units/capsule) for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 daily capsule of placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain</intervention_name>
    <description>Patients allocated to the probiotic arm will take the dietary supplement, containing 15 billion of the Lacticaseibacillus rhamnosus CA15 (DSM 33960) probiotic strain, once a day for 10 consecutive days.</description>
    <arm_group_label>Active</arm_group_label>
    <other_name>probiotic CA15</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients allocated to placebo arm will take placebo capsules once a day for 10 consecutive days.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Presence of at least one vaginal sign or symptom (leucorrhoea, burning, itching,&#xD;
             subjective vaginal discomfort);&#xD;
&#xD;
          -  Presence of at least 3 Amsel criteria;&#xD;
&#xD;
          -  Nugent score greater than 7;&#xD;
&#xD;
          -  Lactobacillary grade greater than 2 (LBG) (according to Donders classification);&#xD;
&#xD;
          -  Vaginal dysbiosis based on microbial cell count.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of sexually transmitted diseases due to Chlamydia, Neisseria gonorrhoeae or&#xD;
             Trichomonas vaginalis as well as specific cervico-vaginitis or severe vulvovaginal&#xD;
             symptoms related to acute candidiasis;&#xD;
&#xD;
          -  Clinically evident herpes simplex infection;&#xD;
&#xD;
          -  Human papillomavirus or human immunodeficiency virus infections;&#xD;
&#xD;
          -  Use of antibiotics, antifungals, probiotics, or immunosuppressants within the past&#xD;
             four weeks;&#xD;
&#xD;
          -  Use of vaginal contraceptives and any other physiological or pathological condition&#xD;
             that could potentially interfere with the results of the study (e.g. pregnancy or&#xD;
             breastfeeding, chronic diseases, neoplastic diseases, diabetes, genital tract&#xD;
             hemorrhages);&#xD;
&#xD;
          -  Enrollment in other programs that involve the administration of products that may&#xD;
             affect the composition of the vaginal microbiota.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Women under reproductive age</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>48 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marco M Panella, Prof</last_name>
    <role>Study Director</role>
    <affiliation>University of Catania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marco M Panella, Prof</last_name>
    <phone>+390953781102</phone>
    <email>mpanella@unict.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Catania</name>
      <address>
        <city>Catania</city>
        <zip>95123</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marco M Panella, Prof</last_name>
      <phone>0953781102</phone>
      <phone_ext>+39</phone_ext>
      <email>mpanella@unict.it</email>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>April 2023</verification_date>
  <study_first_submitted>March 21, 2023</study_first_submitted>
  <study_first_submitted_qc>March 21, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2023</study_first_posted>
  <last_update_submitted>April 6, 2023</last_update_submitted>
  <last_update_submitted_qc>April 6, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universita degli Studi di Catania</investigator_affiliation>
    <investigator_full_name>Agnese Maria Chiara Rapisarda</investigator_full_name>
    <investigator_title>doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Tract Infections</mesh_term>
    <mesh_term>Vaginosis, Bacterial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

